Previously, we have shown that olanzapine challenge associates an increased expression of Tcf7l2 in non-pancreatic tissues and concomitant dyslipidemia (Li et al., 2018), highlighting an active interaction between olanzapine and Tcf7l2. Here, TCF7L2 is linked to metabolic syndrome.